ArticleAdvanced healthcare materials2026
One-Step Microfluidic Manufactured Fucose-Decorated Sweetosomes Choose the Time and the Road for Their Intracellular Journey to Cancer Treatment.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Carbohydrate‑functionalized liposomes are promising drug‑delivery systems due to their biocompatibility, biodegradability, low toxicity, and ability to mediate targeted cell interactions. However, conventional functionalization strategies rely on multi‑step chemical conjugations that introduce variability, hinder large‑scale production, and compromise formulation stability. Here, we overcome these limitations by achieving liposome functionalization without surface chemistry. We introduce "sweetosomes," a newly formulated class of sugar‑decorated liposomes designed for cancer targeting, which promote more specific and active cellular uptake, prolonged intracellular retention, and enhanced endosomal escape. We show that organelle acidity can be selectively modulated by fucosylated sweetosomes, supporting their role in facilitating endosomal escape an essential step for the cytoplasmic delivery of biological therapeutics. Fucosylated sweetosomes and blank liposomes enter cells but traffic through distinct endosomal pathways; indeed, fucose residues appear to alter endosomal maturation and function. Our findings validate fucosylated sweetosomes as optimized lipid nanostructures for intestinal cancer targeting, demonstrating significantly improved curcumin delivery, primarily via the caveolae pathway. Finally, fucosylated sweetosomes highlight translational potential, due to their prolonged plasma persistence, as detected by ex vivo plasma and blood‑cell analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.